Calibrated for Someone Else: How Elderly Americans Bear the Pharmacological Burden of Trials That Excluded Them

Every prescription written for an 81-year-old with heart failure, type 2 diabetes, and chronic kidney disease carries an implicit assumption: that the clinical evidence informing that dose applies to this patient. In the vast majority of cases, it does not. The dosing recommendations embedded in US prescribing guidelines are derived overwhelmingly from trials enrolling adults between the ages of 40 and 65—a population whose pharmacological profile bears diminishing resemblance to the geriatric patients who receive the same milligram-for-milligram instructions.

This is not a matter of extrapolation at the margins. It is a structural misalignment between the population studied and the population treated, and its downstream effects are measurable in emergency department admissions, prolonged hospitalizations, and avoidable deaths.

A Body That Processes Differently

The pharmacological differences between a 50-year-old and a 78-year-old are not subtle. Aging introduces a cascade of physiological changes that alter every phase of drug disposition. Body composition shifts toward lower lean mass and higher fat-to-water ratios, redistributing lipophilic compounds in ways that extend their half-lives. Hepatic blood flow and cytochrome P450 enzyme activity decline with age, reducing first-pass metabolism and slowing hepatic clearance. Most significantly, glomerular filtration rate decreases in the majority of adults over 70, diminishing renal drug clearance even when serum creatinine appears within normal range—a well-documented measurement artifact that routinely leads clinicians to overestimate renal function in elderly patients.

The clinical consequence of these changes is not theoretical. Drug plasma concentrations in older adults frequently exceed those observed in trial populations at identical doses, producing toxic exposures where therapeutic ones were intended. Digoxin, warfarin, metformin, direct oral anticoagulants, and numerous antihypertensives all carry heightened adverse event profiles in elderly patients—profiles that are predictable from pharmacokinetic principles yet underrepresented in the guidance documents clinicians consult.

The Data Exists. The Protocols Don't Reflect It.

What makes this problem particularly difficult to justify is the existence of a substantial body of geriatric pharmacokinetic research that has not been translated into actionable clinical guidance. Age-stratified pharmacokinetic analyses, population modeling studies, and geriatric-specific dosing investigations have been published across disciplines for decades. The American Geriatrics Society's Beers Criteria, last updated in 2023, identifies dozens of medications considered potentially inappropriate for older adults—yet these designations remain advisory rather than structurally embedded in prescribing systems or FDA-approved labeling.

The FDA has issued guidance on pharmacokinetic studies in geriatric populations, and the agency's 1994 guidance document explicitly encouraged sponsors to enroll patients over 65 in drug trials. Thirty years later, compliance with that encouragement remains inconsistent. An analysis of trials supporting new drug applications between 2010 and 2020 found that adults over 75 represented fewer than 5% of enrolled participants across therapeutic categories, despite comprising a disproportionate share of the eventual prescribing population.

The disconnect is not simply a matter of trial enrollment demographics. Even when geriatric data is collected, it is rarely disaggregated into the labeling information that shapes clinical practice. Dosing tables in prescribing information commonly stratify by renal function or hepatic impairment but do not independently address age as a variable—despite age's independent contribution to pharmacokinetic variability beyond organ function metrics.

Polypharmacy as a Compounding Variable

The pharmacological vulnerability of elderly patients is not confined to single-drug kinetics. The average Medicare beneficiary takes four to five prescription medications; a substantial subset takes ten or more. Drug-drug interactions in this context do not follow simple additive logic. They operate through shared metabolic pathways, competing protein binding, and synergistic effects on organ systems already operating with reduced reserve.

Clinical trial design, by contrast, typically enforces strict exclusion criteria that eliminate polypharmacy patients from enrollment. The trial population that generates dosing data is, by design, pharmacologically cleaner than the elderly patient receiving the resulting recommendation. The dose that was safe in a medically uncomplicated 58-year-old may be dangerous in a 76-year-old managing five concurrent conditions with seven concurrent medications—and no trial has studied that combination.

What Structural Reform Would Require

Addressing this gap requires intervention at multiple levels simultaneously. At the regulatory level, mandatory geriatric pharmacokinetic substudies should be required components of new drug applications for any compound likely to be prescribed to patients over 65—not optional supplements. Age-stratified dosing recommendations should appear in approved labeling as standard rather than exceptional practice.

At the clinical decision-support level, electronic health record systems should incorporate renal-function-adjusted dosing calculators that use validated geriatric estimation tools—such as the CKD-EPI equation with age weighting—rather than defaulting to creatinine-based estimates that systematically misclassify elderly patients as having adequate renal clearance.

At the research infrastructure level, funding bodies including the National Institute on Aging and the Patient-Centered Outcomes Research Institute should prioritize pharmacokinetic trials enrolling adults over 75 with realistic comorbidity profiles. The evidence base for geriatric prescribing will not self-correct through incremental publication; it requires deliberate investment in a population that has been systematically underrepresented.

The Clinical Cost of Inaction

Adverse drug events account for approximately 100,000 hospitalizations annually among adults over 65 in the United States, according to estimates from the Centers for Disease Control and Prevention. A meaningful proportion of these events involve medications prescribed at doses calibrated for younger, pharmacologically simpler patients. The harm is not random—it is predictable from known pharmacokinetic principles and known population characteristics.

America's population of adults over 65 is projected to reach 80 million by 2040. The prescribing systems serving that population are operating on evidence generated largely without them. Closing that gap is not a peripheral concern for geriatric specialists; it is a foundational obligation for clinical medicine at scale.